This second annual Special Issue on Antibodies is the result of an increasingly successful partnership between Protein Engineering Design and Selection (PEDS) and The Antibody Society, which adopted PEDS as its official journal. Although important papers in the broad field of engineered antibodies, single-scaffold binding protein and related computational advances appear in PEDS throughout the year, this issue is particularly exciting because of its exclusive focus on this field. A large group of authors, an extensive number of reviewers, outstanding editors, the exceptional editorial staff at PEDS and a dedicated team at Oxford University Press have all participated to make this issue a reality. Members of The Antibody Society are very grateful for their tireless efforts.
The Antibody Society continues to develop rapidly and has seen growth of its membership, the addition of an extensive Board of Distinguished Advisors and incorporation of the Antibody Society Research and Education Foundation, which will be developed to enhance funding in our field to help ensure its long-term success and vitality. Plans are now underway for our Annual Meeting, to be held in San Diego on 5 -9 December 2010. An interactive Drupal-based website is rapidly being constructed that will facilitate the formation of subgroups with focused interests. Our continued development depends on the participation of the broad antibody community, and our website serves as our village green, where you may join us in helping our field to thrive (http://www.AntibodySociety.org). Graduate students pay no fee, and others are minimal, but online registration is important to future interactive plans. Support from our Corporate Sponsors is greatly appreciated and essential to our future development programs.
Research and development of antibodies, especially those intended as therapeutics, have expanded rapidly during the past decade, as their remarkable versatility has been explored and exploited by scientists in the government, academic and commercial sectors. Design of a therapeutic antibody is a process that requires consideration of numerous variables and optimization when possible. This process has been used successfully to produce over 25 recombinant antibodies that are currently on the market. The top 10 best-selling of these products earned over $32 billion in global sales during 2008, and five mAb products (infliximab, rituximab, bevacizumab, trastuzumab and adalimumab) were included in the top 15 best-selling prescription drugs for that year. The future prospects for therapeutic antibodies are clearly bright, with their compound annual growth rate estimated to be 12% during 2010 -2012.
The commercial pipeline of candidates is robust and growing at a rate of 40 new antibodies per year. Alternative scaffolds are the subject of two papers. Hackel and Wittrup explore the consequences of designing either two amino acid-or 20 amino acid-based diversity in libraries of the 10th type III domain of human fibronectin for generation of high-affinity molecules. A knowledge-based method of altering designed ankyrin repeat protein Off7 to provide reagent-less fluorescent biosensors is reported by BrientLitzler et al.
Research on platform technologies that provide bispecific antibodies is presented in two papers. Davis et al. report their use of a heterodimeric Fc platform technology that allows generation of SEEDbodies, based on strand-exchange engineered domain C H 3 heterodimers, used in this study to produce mono-Fab and IL2 monocytokine models. Orcutt et al. describe production of IgG-scFv bifunctional antibodies constructed by C-terminal fusion of an scFv to the light chains of IgG to provide useful bispecific proteins.
Diagnosis and imaging of cancer using engineered antibody species is discussed in two papers. Olafsen et al. use I-124 anti-CD20 scFv dimers (diabodies) for the detection of low-grade lymphomas by immunoPET imaging. Friedrich et al. present results of their research on production in Escherichia coli of the Fab fragment of mouse mAb cmHsp70.1, which is a reagent with potential as a tumor diagnostic. They found that the expression level was dramatically increased in the presence of pTUM14, a folding helper plasmid.
Two papers explore the generation of immunofusion proteins intended to modulate the in vivo properties of functional fusion partners. Taylor et al. report on the production of anti-glycophorin 10F7 scFv-Epo fusion proteins comprising a reduced-affinity Epo analog that, in this novel format, demonstrates greatly enhanced red blood cell-lineage specificity. Walker et al. discuss the use of serum albumin fusions with a domain antibody (dAbs) and also to interferon-a2b as an example of how this HSAbody approach extends the serum half-life of dAbs-targeted therapeutics.
Additional papers present results in other diverse areas of antibody research and development. Sgier et al. report on scFv selection with affinity maturation to obtain DS2 scFv, and characterization of the DS2 anti-urokinase-type plasminogen activator antibody (scFv and IgG formats) that unexpectedly displayed pan-tumoral specificity suitable for pharmacodelivery of therapeutic fusion partners in cancer therapy. 
